Success Stories: Thanks to Premium Processing, a Chinese Research Scientist in Biomedical Science Gets EB1-A Approval in Just 8 Days
Client’s Testimonial:
“Thank you so much for your efficiency and professionalism, my case was approved so smoothly. I am so glad to select Chen Immigration Team as my professional support for my green card application!”
On August 30th, 2021, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Scientist in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Research Scientist
Country of Origin: China
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: August 30th, 2021
Processing Time: 8 days (Premium Processing Requested)
Case Summary:
USCIS has laid out strict guidelines for the qualifying criteria under the EB1-A (Alien of Extraordinary Ability) category. This means that the petitioner needs to prove beyond reasonable doubt that their case has merit by showing that their work is valuable to the United States of America. This process can be both tiring and time-consuming for anyone who is unfamiliar with the system. This is where North America Immigration Law Group comes in. We help clients from all over the world to understand and remain ahead of the curve, leading them to certain success.
Last year in August a client from China came to us asking for help with his EB1-A case. He was an international postdoctoral associate working in the very competitive field of biomedical science. Armed with a Ph.D. in neuroscience, he wanted us to build a winning case for him. So our attorney suggested that he provide us with his updated CV and other relevant documents. Our team then took over and gleaned information about his academic and professional background.
We were able to find that he has spent years investigating issues related to neuroscience and ischemic stroke and is regarded as an authority in the field. The field has recognized his expertise by inviting him to review and evaluate the work of his peers a total of 25 times. These peer reviews were conducted for leading international journals in his field of expertise. Moreover, he has actively engaged his peers in the field of biomedical science by authoring and co-authoring 21 peer-reviewed scientific articles, and 1 book chapter that has been published in international journals. Due to its great applicability in the field, this research in biomedical science has been cited 391 times. This includes 323 citations according to Google Scholar and an additional 68 citations according to China National Knowledge Infrastructure (CNKI).
These citations of his publications have been cited by researchers in at least 35 countries according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of biomedical science.
On the other hand, his study has been supported by funding from the Spanish Ministry of Economy and Competitiveness (MINECO), the Flanders Fund for Scientific Research, COST Action, and the Miguel Servet Program. This support of his research, therefore, serves as evidence that his research is cutting-edge in the field and essential to public health. His study has also received funding from the National Institutes of Health. This funding supports medical research that fundamentally promotes public health in the United States. These institutions fund projects that promote scientific innovation and basic research aimed at improving society in general.
To further support his claim, we included excerpts from letters of support in their application, two of which are quoted below:
“In light of the substantial burden of Alzheimer’s disease on American citizens, research that helps to identify new, more effective treatments is clearly of great value to the U.S. By identifying a new source of safe, natural candidate drugs for the treatment of Alzheimer’s disease, [the client] has helped to enhance the country’s ability to reduce or prevent the development of Alzheimer’s disease.”
“Considering the profound impact that stroke has on both individuals and the United States healthcare system, [the client’s] research relating to the underlying mechanisms of stroke recovery and mediation is quite vital. His research aims to reduce the damage done during stroke events through uncovering novel therapies based on the molecular and cellular mechanisms triggered during strokes.”
All of this information put together made for an impressive application and we are happy to know of its approval in just 8 days. We wish him the best in all of his future endeavors.